{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-25-000018","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2025-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.715893+00:00","generated_at":"2026-05-17T07:02:23.990984+00:00","sec_items":["8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AbCellera appoints Sarah Noonberg as first Chief Medical Officer","bullets":["Dr. Sarah Noonberg appointed CMO effective September 10, 2025; she is AbCellera's first CMO.","Noonberg brings over 20 years experience, previously CMO at Metagenomi and other biotechs.","She will lead clinical development of AbCellera's antibody-based therapeutic pipeline.","Appointment marks company transition from discovery to clinical-stage organization."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-25-000018","json":"https://secwatch.observer/filing/0001703057-25-000018.json","markdown":"https://secwatch.observer/filing/0001703057-25-000018.md","text":"https://secwatch.observer/filing/0001703057-25-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305725000018/0001703057-25-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305725000018/abcl-20250910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:02:23.990984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}